|
Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2011 Jun 21;57(25):2496-504. doi: 10.1016/j.jacc.2010.12.033. Epub 2011 Apr 14. PubMed PMID: 21497043.
AÑO: 2011; IF: 14.156
|
21497043
|
Orenes-Piñero E, Hernández-Romero D, Jover E, Valdés M, Lip GY, Marín F. Impact of polymorphisms in the renin-angiotensin-aldosterone system on hypertrophic cardiomyopathy. J Renin Angiotensin Aldosterone Syst. 2011 Dec;12(4):521-30. doi: 10.1177/1470320311405247. Epub 2011 Apr 20. Review. PubMed PMID: 21507890.
AÑO: 2011; IF: 2.439
|
|
Orenes-Piñero E, Hernández-Romero D, Jover E, de la Morena G, Valdés M, Marín F. An insight of novel pharmacological therapies in hypertrophic cardiomyopathy. Med Chem. 2011 Jul;7(4):275-85. Review. PubMed PMID: 21568880.
AÑO: 2011; IF: 1.496
|
|
Muñoz-Esparza C, Jover E, Hernández-Romero D, Saura D, Valdés M, Lip GY, Marín F. Interactions between clopidogrel and proton pump inhibitors: a review of evidence. Curr Med Chem. 2011;18(16):2386-400. Review. PubMed PMID: 21568918.
AÑO: 2011; IF: 4.859
|
|
Hernández-Romero D, Marín F, Lee KW, Roldán V, Caturla J, Corral J, Valdés M, Lip GY, Vicente V, González-Conejero R. Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction. Thromb Haemost. 2010 Sep;104(3):650-2. doi: 10.1160/TH10-01-0022. Epub 2010 Jun 29. PubMed PMID: 20589311.
AÑO: 2010; IF: 4.701
|